Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eastwood Bio-Medical CanadaTSXV:EBM +1.02%25 Gross Margin % is 80.00% as of Apr. 2026, which is 63% above its 10-year median of 49.09. GuruFocus rates TSXV:EBM with a GF Score™ of 25/100 and a GF Value™ of C$0.53 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 732 Biotechnology companies, Eastwood Bio-Medical Canada ranks better than 62.84% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Eastwood Bio-Medical Canada had a gross margin of 80.00% for the quarter that ended in Apr. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Eastwood Bio-Medical Canada Gross Margin % Related Terms
Eastwood Bio-Medical Canada Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:EBM vs VRTX, REGN, RVMD: Gross Margin % Comparison
For the Biotechnology subindustry, Eastwood Bio-Medical Canada's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eastwood Bio-Medical Canada Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Eastwood Bio-Medical Canada's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Eastwood Bio-Medical Canada's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Eastwood Bio-Medical Canada (TSXV:EBM) has a Gross Margin % of 80.00% as of Apr. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Eastwood Bio-Medical Canada and its competitors. This is 63% above median its historical median of 49.09. Over the past decade, Eastwood Bio-Medical Canada's Gross Margin % has ranged from 25.07 to 73.06. According to the industry distribution chart, Eastwood Bio-Medical Canada ranks #272 out of 732 companies in the Biotechnology industry, placing it in the top 37.2%.
Is Eastwood Bio-Medical Canada's Gross Margin % too high?
Eastwood Bio-Medical Canada's current Gross Margin % of 80.00% is 63% above median its 10-year median of 49.09. Over the past 10 years, this metric has ranged from a low of 25.07 to a high of 73.06. The Biotechnology industry median Gross Margin % is 60.92. Eastwood Bio-Medical Canada's value of 80.00% is 31.3% above this industry median. Based on the distribution chart, Eastwood Bio-Medical Canada ranks #272 out of 732 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Eastwood Bio-Medical Canada has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Eastwood Bio-Medical Canada's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Eastwood Bio-Medical Canada ranks #272 out of 732 companies for Gross Margin %. This puts Eastwood Bio-Medical Canada in the upper half of its industry. The industry median Gross Margin % is 60.92. Eastwood Bio-Medical Canada's value of 80.00% is 31.3% above this benchmark. Historically, Eastwood Bio-Medical Canada's own Gross Margin % has ranged from 25.07 to 73.06 over the past decade. While the company's 10-year median is 49.09 vs. the industry median of 60.92, Eastwood Bio-Medical Canada has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.92, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eastwood Bio-Medical Canada's current Gross Margin % of 80.00% is 31.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Eastwood Bio-Medical Canada and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eastwood Bio-Medical Canada's current Gross Margin % is 80.00%, which is 63% above median its own 10-year median of 49.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eastwood Bio-Medical Canada stock overvalued right now?
Based on GuruFocus' analysis, Eastwood Bio-Medical Canada (TSXV:EBM) is currently considered Significantly Overvalued. The stock's GF Value™ is C$0.53, compared to a current price of C$0.99 — trading 86.8% above its estimated fair value. The current Gross Margin % is 80.00%, which is 63% above median its 10-year median of 49.09 and 31.3% above the Biotechnology industry median of 60.92. Eastwood Bio-Medical Canada's overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Eastwood Bio-Medical Canada (TSXV:EBM), the current Gross Margin % is 80.00% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eastwood Bio-Medical Canada (TSXV:EBM) Overvalued in 2026?
Based on GuruFocus' analysis, Eastwood Bio-Medical Canada stock appears to be overvalued.
The current stock price of C$0.99 is trading 86.8% above its estimated GF Value™ of C$0.53.
GuruFocus considers Eastwood Bio-Medical Canada to be Significantly Overvalued.
Key valuation signals for TSXV:EBM:
Gross Margin %: 80.00% (63% above median its 10-year median of 49.09)
GF Value™: C$0.53 vs. price of C$0.99 (86.8% above fair value)
Industry Position: 31.3% above the Biotechnology median (#272 of 732)
No single metric tells the full story. See the TSXV:EBM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eastwood Bio-Medical Canada Inc is a Canadian company engaged in the development and commercialization of safe and effective treatment for non-insulin dependent diabetes mellitus. The company is engaged in natural health supplement distribution company. It has its geographic presence in U.S., Canada and Asia. The company generates maximum revenue from Asia.
25GF Score
Get the complete analysis for TSXV:EBM
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:EBM has been successfully added to your 
